<DOC>
	<DOC>NCT02142725</DOC>
	<brief_summary>The purpose of this study is to compare two different dosing regimens of phosphatidylcholine versus placebo for the induction of remission in ulcerative colitis patients non-responsive to standard mesalamine treatment.</brief_summary>
	<brief_title>Phosphatidylcholine (LT-02) for Induction of Remission in Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Established diagnosis of ulcerative colitis Active ulcerative colitis disease extent â‰¥ 15 cm Active disease despite treatment with mesalamine Crohn's disease, indeterminate colitis, ischemic colitis, radiation colitis, microscopic colitis, diverticular disease associated colitis, Toxic megacolon or fulminant colitis Colon resection Evidence of infectious colitis Celiac disease Bleeding hemorrhoids History or presence of ischemic heart disease, myocardial infarction, peripheral arterial disease, ischemic stroke, or transient ischemic attack Any severe concomitant renal, endocrine, or psychiatric disorder Any relevant known systemic disease History of cancer in the last five years Abnormal hepatic function or liver cirrhosis Abnormal HbA1c at screening visit Patients with known hypersensitivity to soy Known intolerance/hypersensitivity to Investigational Medicinal Product (IMP) Treatment with steroids/methotrexate/Tumor necrosis factoralphaantagonists/azathioprine/ 6mercaptopurine/antiintegrin/coumarins Treatment with other investigational drug Existing or intended pregnancy or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>